Skip to content

Medical-device intelligence

NIG: System, Test, Carbohydrate Antigen (Ca19-9), For Monitoring And Management Of Pancreatic Cancer

FDA product code NIG: System, Test, Carbohydrate Antigen (Ca19-9), For Monitoring And Management Of Pancreatic Cancer. View classification details, related manufacturers, 510(k) clearances, and recall records.

FDA classification ↗

Classification details

Product code
NIG
FDA device name
System, Test, Carbohydrate Antigen (Ca19-9), For Monitoring And Management Of Pancreatic Cancer
Device class
2
Regulation number
866.6010
Medical specialty
Immunology
Review panel
IM

FDA definition

An in vitro diagnostic test for the quantitative measurement of the CA 19-9 tumor associated antigen in human serum or plasma. The test is intended as an aid in the management of patients with confirmed pancreatic cancer and serial monitoring of their response to therapy and disease progression. The test should only be used in patients with serum and plasma CA 19-9 values above the cut-off at the time of diagnosis and in conjunction with other clinical methods.
Explore immunology records →
A product code groups records by FDA classification. It does not establish identical intended uses, commercial availability, or comparative device safety.

Record activity in this scope

12 clearance records and 19 recall records in the covered releases, across 12 source company names and 1 product codes. Dated history runs from May 9, 2002 to Aug 10, 2026.

Monthly counts through October 2026
Month510(k) decisionsRecall initiations
October 202500
November 202500
December 202500
January 202600
February 202600
March 202600
April 202600
May 202600
June 202600
July 202600
August 202610
September 202600
October 202600

Product codes represented

All-history totals use the covered releases; monthly counts stop at the last calendar month covered by both sources. Clearances use decision dates; recalls use initiation dates. 0 records lack the required date and are excluded from monthly counts. These are records, not product launches, market share, incidence rates, or comparative safety. Feed filters below do not change this overview.

Clearances and recall records

31 matching records
Device / recordCompany in FDA recordSourceSource date
ARCHITECT CA 19-9 Reagent Kit, list 6C04-20 (1 x 100 tests) and 6C04-25 (4 x 100 tests), Abbott laboratories, Abbott Park, IL 60064 U.S.A.Z-0781-04 · NIGAbbott Laboratories HPD/ADD/GPRDRecallJul 20, 2004FDA classification date
GI MONITOR AND GI MONITOR CALIBRATORS ON THE ACCESS IMMUNOASSAY SYSTEMS, MODEL 387687, 387688K033038 · NIGBeckman Coulter, Inc.510(k)Dec 29, 2003FDA decision date
BAYER ADVIA CENTAUR CA 19-9 ASSAYK031393 · NIGBayer Healthcare, LLC510(k)Jun 24, 2003FDA decision date
AIA-PACK CA 19-9K023239 · NIGTosoh Corp.510(k)Dec 23, 2002FDA decision date
ST AIA-PACK CA 19-9K023240 · NIGTosoh Corp.510(k)Dec 23, 2002FDA decision date
FUJIREBIO DIAGNOSTICS CA 19-9 RIAK020566 · NIGFujirebio Diagnostics,Inc.510(k)May 9, 2002FDA decision date

Manufacturers in these records

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗